D. Trummer

发表

Investigation of the Hemostatic Effect of a Transdermal Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene Compared with a Monophasic Oral Contraceptive Containing 0.03 mg Ethinyl Estradiol and 0.15 mg Levonorgestrel: An Open-Label, Randomized, Crossover Study

D. Heger-Mahn, M. Merz, W. Junge, 2013, Drugs in R&D.

Bioequivalence Evaluation of a Folate-Supplemented Oral Contraceptive Containing Ethinylestradiol/Drospirenone/Levomefolate Calcium versus Ethinylestradiol/Drospirenone and Levomefolate Calcium Alone

K. Diefenbach, B. Rohde, H. Wiesinger, 2012, Clinical Drug Investigation.

Original research article Pituitary, ovarian and additional contraceptive effects of an estradiol-based combined oral contraceptive: results of a randomized, open-label study

J. Endrikat, C. Klipping, M. Serrani, 2013 .

Pituitary, ovarian and additional contraceptive effects of an estradiol-based combined oral contraceptive: results of a randomized, open-label study.

J. Endrikat, C. Klipping, M. Serrani, 2013, Contraception.

Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study.

J. Jensen, D. Trummer, J. Elliesen, 2012, Contraception.

Contraceptive efficacy and tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study

C. Klipping, Michel P Fortier, J. Marr, 2012, Journal of Family Planning and Reproductive Health Care.

Long-term tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study

C. Klipping, Michel P Fortier, J. Marr, 2012, Journal of Family Planning and Reproductive Health Care.

Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies.

J. Endrikat, C. Klipping, W. Schmidt, 2008, Contraception.

Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen.

L. Hernadi, F. Petraglia, V. de Leo, 2009, Contraception.

Hormone withdrawal-associated symptoms with ethinylestradiol 20 μg/drospirenone 3 mg (24/4 regimen) versus ethinylestradiol 20 μg/desogestrel 150 μg (21/7 regimen)

J. Restrepo, J. Bitzer, D. Trummer, 2015, International journal of women's health.

EE-drospirenone-levomefolate calcium versus EE-drospirenone + folic acid: folate status during 24 weeks of treatment and over 20 weeks following treatment cessation

K. Diefenbach, B. Rohde, H. Blode, 2013, International journal of women's health.

Bioequivalence study of an oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium relative to ethinylestradiol/drospirenone and to levomefolate calcium alone.

K. Diefenbach, B. Rohde, C. Klipping, 2012, Contraception.

Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: a randomized, double-blind, active-controlled, parallel-group, US-based multicenter study.

K. Diefenbach, J. Marr, D. Trummer, 2012, Contraception.

Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen.

C. Klipping, J. Marr, I. Duijkers, 2008, Contraception.

Applying Ant Colony Optimization to the Periodic Vehicle Routing Problem with Time Windows

Dietmar Trummer, D. Trummer, 2014 .

Efficacy, safety and tolerability of the CCR1 antagonist BAY 86‐5047 for the treatment of endometriosis‐associated pelvic pain: a randomized controlled trial

H. Schmitz, D. Trummer, E. Groettrup-Wolfers, 2017, Acta obstetricia et gynecologica Scandinavica.

Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies.

J. Endrikat, C. Klipping, W. Schmidt, 2008, Contraception.